Published in J Clin Oncol on July 01, 2001
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse | NCT00003673
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) | NCT00143975
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood (2013) 3.91
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood (2012) 2.03
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 1.99
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood (2005) 1.93
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol (2014) 1.79
Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol (2012) 1.57
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study. J Clin Oncol (2010) 1.43
Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol (2011) 1.33
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia (2014) 1.32
Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res (2013) 1.26
Recent advances in acute myeloid leukemia stem cell biology. Haematologica (2012) 1.25
Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol (2013) 1.18
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood (2012) 1.10
Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol (2009) 1.09
Driving CAR T-cells forward. Nat Rev Clin Oncol (2016) 1.09
Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther (2014) 1.06
Childhood acute myeloid leukaemia. Br J Haematol (2012) 1.04
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed) (2013) 1.01
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 0.98
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. J Clin Oncol (2008) 0.94
Treatment of acute myeloid leukemia. Haematologica (2009) 0.94
Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin. Invest New Drugs (2012) 0.93
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. Onco Targets Ther (2014) 0.93
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood (2011) 0.92
Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia. Ann Hematol (2014) 0.90
Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leuk Lymphoma (2013) 0.90
The evolving landscape in the therapy of acute myeloid leukemia. Protein Cell (2013) 0.90
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. MAbs (2016) 0.90
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica (2012) 0.88
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J (2014) 0.88
Mucosal injury from targeted anti-cancer therapy. Support Care Cancer (2006) 0.88
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol (2016) 0.87
Novel agents for the treatment of childhood acute leukemia. Ther Adv Hematol (2015) 0.87
Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. Haematologica (2014) 0.86
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica (2011) 0.86
Novel targeted drug therapies for the treatment of childhood acute leukemia. Expert Rev Hematol (2009) 0.85
Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant (2014) 0.85
Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol (2004) 0.85
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant (2011) 0.84
Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother (2008) 0.84
Treating refractory leukemias in childhood, role of clofarabine. Ther Clin Risk Manag (2008) 0.84
Disubstituted Sialic Acid Ligands Targeting Siglecs CD33 and CD22 Associated with Myeloid Leukaemias and B Cell Lymphomas. Chem Sci (2014) 0.84
Molecular therapeutic approaches for pediatric acute myeloid leukemia. Front Oncol (2014) 0.83
Therapeutics formulated to target cancer stem cells: Is it in our future? Cancer Cell Int (2011) 0.83
Advances in the treatment of hematologic malignancies using immunoconjugates. Blood (2014) 0.83
Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep (2010) 0.82
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges. Int J Nanomedicine (2015) 0.82
Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res (2007) 0.81
Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. Blood Cancer J (2014) 0.80
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica (2011) 0.80
Therapeutic monoclonal antibodies in oncology. J R Soc Med (2005) 0.79
A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. Leukemia (2015) 0.79
Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology (2013) 0.79
Update on optimal management of acute myeloid leukemia. Clin Med Insights Oncol (2013) 0.79
Treatment concepts for elderly patients with acute myeloid leukemia. Wien Klin Wochenschr (2003) 0.79
Acute myeloid leukaemia in 2012: En route to improved treatment options. Nat Rev Clin Oncol (2013) 0.78
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers (Basel) (2012) 0.78
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol (2010) 0.78
Relationship between ganglioside expression and anti-cancer effects of the monoclonal antibody against epithelial cell adhesion molecule in colon cancer. Exp Mol Med (2011) 0.78
Generation of Pediatric Leukemia Xenograft Models in NSG-B2m Mice: Comparison with NOD/SCID Mice. Front Oncol (2016) 0.77
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin. Clin Interv Aging (2009) 0.77
What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma (2009) 0.76
Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells (2016) 0.76
A Humanized Anti-CD22-Onconase Antibody-Drug Conjugate Mediates Highly Potent Destruction of Targeted Tumor Cells. J Immunol Res (2015) 0.76
Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse. Invest New Drugs (2002) 0.76
Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute. J Natl Cancer Inst (2015) 0.75
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res (2015) 0.75
Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia. BMC Cancer (2006) 0.75
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20(+) B-cell lymphoma. Sci Rep (2017) 0.75
Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biol Blood Marrow Transplant (2015) 0.75
Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol (2016) 0.75
Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. Front Oncol (2015) 0.75
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk MDS. Haematologica (2017) 0.75
Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments. Target Oncol (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. Adv Ther (2017) 0.75
[Risk-adapted therapy of acute myeloid leukemia]. Internist (Berl) (2006) 0.75
Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol (1983) 14.36
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol (1976) 13.98
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
High gamma power is phase-locked to theta oscillations in human neocortex. Science (2006) 10.40
Changes in physicians' attitudes toward telling the cancer patient. JAMA (1979) 7.75
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 6.82
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia (2009) 6.29
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med (1980) 6.12
Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98
Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases. Cancer (1981) 5.89
Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A (1997) 5.61
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol (1986) 5.27
Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res (2001) 4.87
All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med (2000) 4.55
Immunophenotyping of blood lymphocytes in childhood. Reference values for lymphocyte subpopulations. J Pediatr (1997) 3.80
Analysis of cell populations with a fluorescence-activated cell sorter. Ann N Y Acad Sci (1975) 3.76
Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med (2000) 3.70
Onset of DNA synthesis during the cell cycle in chemostat cultures. Proc Natl Acad Sci U S A (1967) 3.70
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res (2001) 3.66
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia (2008) 3.58
A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45
Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med (1995) 3.26
Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 3.19
Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18
Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood (1991) 3.12
Cloned T lymphocytes and monoclonal antibodies as probes for cell surface molecules active in T cell-mediated cytolysis. Immunol Rev (1982) 3.06
Diagnosis and management of pituitary abscess: a review of twenty-four cases. J Neurosurg (2001) 3.00
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
The gene encoding the epsilon subunit of the T3/T-cell receptor complex maps to chromosome 11 in humans and to chromosome 9 in mice. Proc Natl Acad Sci U S A (1987) 2.91
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res (2001) 2.78
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience. Blood (2000) 2.65
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol (1986) 2.64
Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia (2003) 2.60
Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J Cell Sci (2000) 2.57
DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells. Cell Death Differ (2006) 2.57
Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol (1993) 2.56
A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia (2003) 2.53
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood (2001) 2.53
Antigen CD34+ marrow cells engraft lethally irradiated baboons. J Clin Invest (1988) 2.53
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53
Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood (2000) 2.53
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52
Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg (2001) 2.39
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience. J Clin Oncol (1995) 2.33
A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32
Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia (2009) 2.30
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood (1986) 2.27
Expression of the c-erbB-2 protein in normal and transformed cells. Int J Cancer (1987) 2.27
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24
Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood (2000) 2.23
Site-specific deletions involving the tal-1 and sil genes are restricted to cells of the T cell receptor alpha/beta lineage: T cell receptor delta gene deletion mechanism affects multiple genes. J Exp Med (1993) 2.23
Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med (1985) 2.22
Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest (2001) 2.21
Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol (1992) 2.19
Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res (2001) 2.16
Allotypic specificities of murine IgD and IgM recognized by monoclonal antibodies. J Immunol (1984) 2.16
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Studies of the human c-myb gene and its product in human acute leukemias. Science (1986) 2.10
Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med (1994) 2.09
Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest (1991) 2.08
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Cortical localization of temporal lobe language sites in patients with gliomas. Neurosurgery (1994) 2.07
Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol (1988) 2.06
The Notch ligand, Jagged-1, influences the development of primitive hematopoietic precursor cells. Blood (1998) 2.05
Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med (1989) 2.05
Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin. J Natl Cancer Inst (1971) 2.04
All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood (1995) 2.04
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Myelodysplastic syndrome and acute nonlymphocytic leukemia secondary to mitolactol treatment in patients with breast cancer. J Clin Oncol (1989) 2.02